|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Meta分析方法系统性分析腹腔镜疝修补术的选择——TEP与TAPP显示文摘腹股沟疝修补术是最常见的手术之一。一个好的疝修补术应该是操作简单、手术时间短、安全。手术结果必须是创伤小、疼痛轻以及复发率低口j。腹腔镜疝修补术和传统的开放式疝修补术(openherniarepair,OHR)相比,术后疼痛轻、对患者限制少。目前,在临床上使用最多的腹腔镜疝修补术方法分别是:经腹腔腹膜前疝修补(transabdominalpreperitoneal,TAPP)和完全腹膜外疝修补(totallyextraperitonealherniarepair,TEP)。本文运用随机对照法研究资料,分析TEP与TAPP孰优孰劣。 | Bracale U Melillo P Pignata G Di Salvo E Rovani M Merola G Pecchia L Surg Endosc 陈大伟 | 2013 | 中华疝和腹壁外科杂志(电子版)2013，7，4： | 15 |
| 2 | Ovarian cancer standard of care: are there real alternatives?显示文摘Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple(primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase(PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase(MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices. | Chiara Della Pepa Giuseppe Tonini Carmela Pisano Marilena Di Napoli Sabrina Chiara Cecere Rosa Tambaro Gaetano Facchini Sando Pignata | 2015 | Chinese Journal of Cancer2015，34，1： | 5 |
| 3 | Effects of heavy metal concentrations (Cd, Zn and Pb) in agricultural soils near different emission sources on quality, accumulation and food safety in soybean [ Glycine max (L.) Merrill]显示文摘 | María Julieta Salazar Judith Hebelen Rodriguez Gastón Leonardo Nieto María Luisa Pignata | 2012 | Journal of Hazardous Materials2012，，： | 2 |
| 4 | Is human hepatocellular carcinoma a hormone-responsive tumor?显示文摘Before the positive results recently obtained with multitarget tyrosine kinase inhibitor sorafenib,there was no standard systemic treatment for patients with advanced hepatocellular carcinoma(HCC).Sex hormones receptors are expressed in a significant proportion of HCC samples.Following preclinical and epidemiological studies supporting a relationship between sex hormones and HCC tumorigenesis,several randomized controlled trials (RCTs)tested the efficacy of the anti-estrogen tamoxifen as systemic treatment.Largest among these trials showed no survival advantage from the administration of tamoxifen,and the recent Cochrane systematic review produced a completely negative result.This questions the relevance of estrogen receptor-mediated pathways in HCC.However,a possible explanation for these disappointing results is the lack of proper patients selection according to sex hormones receptors expression,but unfortunately the interaction between this expression and efficacy of tamoxifen has not been studied adequately.It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway,that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative.Interesting,preliminaryresults have been obtained when hormonal treatment (tamoxifen or megestrol)has been selected according to the presence of wild-type or variant estrogen receptors respectively,but no large RCTs are available to support this strategy.Negative results have been obtained also with anti-androgen therapy.In conclusion,there is no robust evidence to consider HCC a hormone-responsive tumor.Hormonal treatments should not be part of the current management of HCC. | Massimo Di Maio Bruno Daniele Sandro Pignata Ciro Gallo Ermelinda De Maio Alessandro Morabito Maria Carmela Piccirillo Francesco Perrone | 2008 | World Journal of Gastroenterology2008，14，11： | 2 |
| 5 | Ovarian cancer in the elderly显示文摘 | Vermorken JB | 2004 | Crit Rev Oncol Hematol2004，49，： | 1 |
| 6 | Calibration of four species of Tillandsia as air pollution biomonitors 显示文摘 | Wannaz E D Pignata M L | 2006 | Journal of Atmospheric Chemistry2006，53，： | 1 |
| 7 | Phase Ⅱ study of cisplatin and vinorelbmine as first-line chemotherapy in patients with carainoma of the uterine cervix显示文摘 | Pignata S Silveslro G Ferrari E | 1999 | J Clin Oncol1999，17，3： | 1 |
| 8 | Evaluation ofpemetrexed (alimta,ly231514) as second-linechemotherapy in persistent or recurrent carcinoma of thecervix: the cervix 1 study of the mito (multicentre italiantrials in ovarian cancer and gynecologic malignancies)group 显示文摘 | Lorusso D Ferrandina G Pignata S | 2010 | Ann Oncol2010，21，1： | 1 |
| 9 | Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer:aphase Ⅱstudy显示文摘 | Vagno G Connio G Pignata S | 2003 | Int J Gynecol Cancer2003，13，3： | 1 |
| 10 | Comparison among air pollutants, meteorological conditions and some chemical pa- rameters in the transplanted lichen Usnea amblyoclada 显示文摘 | CARRERAS H A PIGNATA M L | 2001 | Environmental Pollution2001，111，1： | 1 |
| 11 | Residual neurotoxicity in ovariancancer patients in clinical remission after first-line chemotherapy with carboplatin andpaclitaxel: the Multicenter Italian Trial in Ovarian Cancer (MITO-4) retrospective study 显示文摘 | Pignata S De Placido S Biamonte R | 2006 | BMC Cancer2006，6，： | 1 |
| 12 | Comparative biomonitoring of atmospheric quality in five zones of Co'rdoba city (Argentina) employing the transplanted lichen Usnea sp显示文摘 | CARRERAS H A GUDINO G L PIGNATA M L | 1998 | Environ Pollut1998，103，： | 1 |
| 13 | Carboplatin and pegylated liposomald-oxorubicin for advanced ovarian cancer:preliminary activity results of the MITO-2 phaseⅢtrial显示文摘 | Pignata S ScambiaG SavareseA | | 0，，： | 1 |
| 14 | Reduced atherosclerot- ic burden in subjects with genetically determined low oxida- tive stress显示文摘 | Vioti F Pignatelli P Pignata C | 2013 | Arterioscler Thromb Vasc Biol2013，33，2： | 1 |
| 15 | Laparoscopic gastrectomies for cancer:The ACOI-IHTSC national guidelines显示文摘 | Bracale U Pignata G Liriei MM | 2012 | Minim Invasive T- her Allied Technol2012，21，5： | 1 |
| 16 | Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth faetor receptor reverse transcriptiou-PCR assay显示文摘 | De Luca A Pignata S Casamassimi A | 2000 | Clin Cancer Res2000，6，4： | 1 |
| 17 | Evaluation of pemetrexed (Alimta, LY231514) as second-line chemo- therapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group显示文摘 | Lorusso D Ferrandina G Pignata S | 2010 | Ann Oncol2010，21，1： | 1 |
| 18 | Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri显示文摘 | Pignata S Frezza P Tramontana S | 2000 | Ann Oncol2000，11，4： | 1 |
| 19 | Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer:a phase study显示文摘 | Vagno G Cormio G Pignata S | 2003 | Int J Gynecol Cancer2003，13，3： | 1 |
| 20 | Transforming growth factor al- pha,amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas显示文摘 | D'Antonio A Losito S Pignata S | 2002 | Int J Oncol2002，21，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员